サンプル依頼リスト カート
  • English
市場調査レポート
商品コード
1723117

抗菌薬耐性診断市場：病原体別、技術別、地域別の戦略と動向 - エグゼクティブコンサルタントガイド付き（2025年～2029年）

Antimicrobial Resistance Diagnostic Markets, Strategies and Trends By Pathogen, By Technology, and By Region with Executive and Consultant Guides. 2025 To 2029

出版日
ページ情報
英文 391 Pages
納期
即日から翌営業日
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=147.28円
抗菌薬耐性診断市場：病原体別、技術別、地域別の戦略と動向 - エグゼクティブコンサルタントガイド付き（2025年～2029年）
出版日: 2025年05月05日
発行: Howe Sound Research
ページ情報: 英文 391 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 図表
  • 目次
概要

レポートの概要

抗菌薬耐性がもたらす脅威を軽減するために、診断薬が主導権を握っています。これらの技術は、新しい抗生物質が登場する前に問題を解決できるのでしょうか。この成長する市場を獲得するため、遺伝子シーケンシングにとどまらない新たな診断技術の開発が進められています。テクノロジーの全体像に目を向け、病原体や感染症を診断するさまざまな方法をわかりやすく理解できるようにしました。この分野における6つの主要な病原体における機会を特定し、市場予測を作成しました。この分野で活躍する大小30以上の企業をプロファイルしています。

最新データを用いて、投資判断とバリュエーションを行うことができます。

当レポートは、世界の抗菌薬耐性診断市場について調査し、市場の概要とともに、病原体別、技術別、地域別動向、および市場に参入する企業のプロファイルなどを提供しています。

目次

第1章 市場ガイド

第2章 イントロダクションと市場の定義

  • 抗菌薬耐性の脅威と機会
  • 機会の定義
  • 方法と情報源
  • 視点：ヘルスケアとIVD業界
  • 診断費

第3章 ダイナミックな市場の概要

  • 市場参入組織
    • 学術研究機関
    • 診断試験開発者
    • 計測機器サプライヤー
    • 薬品・試薬メーカー
    • 病理サプライヤー
    • 独立系臨床検査室
    • 公共の国立/地域研究所
    • 病院検査室
    • 臨床検査室
    • 監査機関
    • 認証機関
  • 抗菌薬耐性について理解する
  • 新しい抗生物質と技術への変化する道
  • AMRにおける診断の重要な役割

第4章 AMRの市場機会

  • AMRにおける主要な大規模市場機会
  • 診断技術開発の機会

第5章 抗生物質耐性診断の最近の動向

第6章 主要なAMR診断企業

  • 1928 Diagnostics
  • Abbott Laboratories
  • Accelerate Diagnostics
  • ADT Biotech
  • Beckman Coulter Diagnostics（Danaher）
  • Becton, Dickinson and Company
  • Binx Health
  • bioMerieux Diagnostics
  • Bio-Rad Laboratories, Inc.
  • Cepheid（Danaher）
  • Curetis（OpGen）
  • Day Zero Diagnostics
  • DeepUII Diagnostics
  • DNAe
  • Enzo Biochem
  • Eurofins Scientific
  • Fusion Genomics
  • GeneFluidics
  • Genetic Signatures
  • Great Basin Scientific, Inc
  • Hologic
  • Hutman Diagnostics
  • Inflammatix
  • Linear Diagnostics
  • Lumos Diagnostics
  • MGI
  • Millipore Sigma
  • OpGen
  • Pathogenomix
  • Qiagen
  • QuidelOrtho
  • Revvity
  • Roche Diagnostics
  • Scope Fluidics
  • SeLux Diagnostics
  • Sherlock Biosciences
  • Siemens Healthineers
  • Sysmex
  • Thermo Fisher Scientific
  • Uniogen
  • Vela Diagnostics
  • Visby Medical

第7章 世界の抗菌薬耐性診断市場

  • 国別世界市場概要
  • 病原体別世界市場- 概要
  • 技術別世界市場- 概要

第8章 世界の抗生物質耐性診断市場- 病原体別

  • 薬剤耐性肺炎球菌-DRSP
  • 薬剤耐性カンピロバクター- コンゴ民主共和国
  • クロストリジウム・ディフィシル-CD
  • メチシリン耐性黄色ブドウ球菌（MRSA）
  • 薬剤耐性淋菌（DRNG）
  • 薬剤耐性サルモネラ菌-DRNTS

第9章 世界の抗生物質耐性診断市場- 技術別

  • 微生物学培養
  • 免疫測定
  • PCR
  • NGS
  • 質量分析法
  • 迅速検査とポイントオブケア

第10章 AMR診断の将来ビジョン

第11章 付録

図表

Table of Tables

  • Table 1: Market Players by Type
  • Table 2: Known Human Pathogenic Diseases
  • Table 3: The Key Market Opportunities
  • Table 4: Market Potential DRSP Diagnostic
  • Table 5: Market Potential DRC Diagnostic
  • Table 6: Market Potential CD Diagnostic
  • Table 7: Market Potential CD Diagnostic
  • Table 8: Market Potential DRNG Diagnostic
  • Table 9: Market Potential DRNTS Diagnostic
  • Table 10: Key AMR Diagnostics Issues
  • Table 11: Global Market by Region
  • Table 12: Global Market by Pathogen
  • Table 13: Global Market by Technology
  • Table 14: DRSP by Country
  • Table 15: DRC by Country
  • Table 16: CD by Country
  • Table 17: MRSA by Country
  • Table 18: DRNG by Country
  • Table 19: DRNTS by Country
  • Table 20: Culture by Country
  • Table 21: Immunoassay by Country
  • Table 22: PCR by Country
  • Table 23: NGS by Country
  • Table 24: MS by Country
  • Table 25: Rapid/POC by Country
  • Table 26: Clinical Lab Fee Schedule

Table of Figures

  • Figure 1: Global Healthcare Spending Map
  • Figure 2: The Lab Test Pie
  • Figure 3: The Road to Diagnostics
  • Figure 4: AMR and Antibiotic Introduction
  • Figure 5: The Death Toll of AMR
  • Figure 6: Global Market Share Chart
  • Figure 7: Global Market by Pathogen - Base vs. End Year
  • Figure 8: Global Market by Pathogen Base Year
  • Figure 9: Global Market by Pathogen End Year
  • Figure 10: Pathogen Share by Year
  • Figure 11: Pathogen Segment Growth
  • Figure 12: Technology - Base vs. End Year Segment Shift
  • Figure 13: Technology Market Base Year
  • Figure 14: Technology Market End Year
  • Figure 15: Technology Share by Year
  • Figure 16: Technology Segment Growth
  • Figure 17: DRSP Growth
  • Figure 18: DRC Diagnostics Growth
  • Figure 19: CD Growth
  • Figure 20: MRSA Growth
  • Figure 21: DRNG Growth
  • Figure 22: DRNTS Growth
  • Figure 23: Culture Growth
  • Figure 24: Immunoassay Growth
  • Figure 25: PCR Growth
  • Figure 26: NGS Growth
  • Figure 27: MS Growth
  • Figure 28: Rapid/POC Growth
目次

Report Overview:

Diagnostics are leading the charge in reducing the threat posed by antimicrobial resistance. Will these technologies solve the problem before new antibiotics come along? New diagnostic technologies, beyond gene sequencing, are under development to capture this growing market. We have looked at the technology picture, giving you plain language understanding of the different ways pathogens, and infections, can be diagnosed. We have identified the 6 Key Large Pathogen Opportunities in this space and developed market forecasts. We profile over 30 companies, large and small, working in this area.

All report data is available in Excel format on request.

Make investment decisions and valuations with confidence using the latest data.

Table of Contents

1. Market Guides

  • 1.1. Antimicrobial Resistance - Strategic Situation Analysis
  • 1.2. Guide for Executives and Business Development Staff
  • 1.3. Guide for Management Consultants and Investment Advisors

2. Introduction and Market Definition

  • 2.1. The Threat and Opportunity of Antimicrobial Resistance
  • 2.2. Defining the Opportunity
    • 2.2.1. Revenue Market Size
  • 2.3. Methods and Sources
    • 2.3.1. Methodology
    • 2.3.2. Sources
    • 2.3.3. Authors
  • 2.4. Perspective: Healthcare and the IVD Industry
    • 2.4.1. Global Healthcare Spending
  • 2.5. Spending on Diagnostics
    • 2.5.1. Important Role of Insurance for Diagnostics

3. Overview of a Dynamic Market

  • 3.1. Players in a Dynamic Market
    • 3.1.1. Diagnostic Test Developer
    • 3.1.2. Instrumentation Supplier
    • 3.1.3. Chemical/Reagent Supplier
    • 3.1.4. Pathology Supplier
    • 3.1.5. Independent Clinical Laboratory
    • 3.1.6. Public National/regional Laboratory
    • 3.1.7. Hospital Laboratory
    • 3.1.8. Physicians Office Lab (POLS)
    • 3.1.9. Audit Body
    • 3.1.10. Certification Body
  • 3.2. Understanding Antimicrobial Resistance
    • 3.2.1. What is Antimicrobial Resistance (AMR)
    • 3.2.2. Bacteria and Other Microbes
    • 3.2.3. The History of Antibiotics
    • 3.2.4. The Role of Animal Husbandry
    • 3.2.5. The Implications of Horizontal Transfer
    • 3.2.6. The Threat of AMR
  • 3.3. The Changing Road to New Antibiotics & Technologies
  • 3.4. The Key Role of Diagnostics in AMR

4. The Market Opportunity of AMR

  • 4.1. The Key Large Market Opportunities in AMR
    • 4.1.1. Streptococcus Pneumoniae (DRSP)
    • 4.1.2. Campylobacter (DRC)
    • 4.1.3. Clostridium Difficile (CD)
    • 4.1.4. Staphylococcus aureus (MRSA)
    • 4.1.5. Neisseria gonorrhoeae (DRNG)
    • 4.1.6. Salmonella (DRNTS)
  • 4.2. Diagnostic Technology Development Opportunities
    • 4.2.1. What's Wrong with Microbiology
    • 4.2.2. The Features Battleground of Infectious Disease Diagnostics
    • 4.2.3. Multiplex vs. POC/Rapid
    • 4.2.4. The Miracle of Genetics
    • 4.2.5. From Multiple Pathogens to All Pathogens - The Next Next Generation
    • 4.2.6. Gene Sequence Diagnostics WITHOUT the Sequencing
    • 4.2.7. Markers of Resistance
    • 4.2.8. What Happens to the Microbiology Lab?

5. Antibiotic Resistance Diagnostics Recent Developments

  • 5.1. Antibiotic Resistance Recent Developments
    • 5.1.1. Importance of These Developments
    • 5.1.2. How to Use This Section
  • 5.2. DeepUll Raises Euro-50M in Oversubscribed Round
  • 5.3. BioMerieux Gets Clearance for ID/AST System
  • 5.4. New antibiotics could treat 'super bugs'
  • 5.5. Cepheid, Fleming Partner to Address AMR
  • 5.6. Fuse Dx and Prompt Dx Funded for POC Tests
  • 5.7. FDA Approval for Karius
  • 5.8. Presymptom Health Develops Sepsis Test
  • 5.9. Visby Medical to Develop STI and AMR MDx
  • 5.10. Siemens Healthineers to Develop NGS-Based Sepsis Test
  • 5.11. Researchers Developing POC Test for Detecting Risk SNPs
  • 5.12. Curetis, FIND Extend AMR Research
  • 5.13. Delve Bio to Develop Metagenomic Dx
  • 5.14. BioMerieux, Oxford Nanopore Form ID Dx Pact
  • 5.15. DnaNudge, Mylab Forge Dx Partnership
  • 5.16. FDA Clears New bioMerieux Diagnostic System and Panel
  • 5.17. Selux Diagnostics Phenotyping System Gets FDA Approval
  • 5.18. New diagnostics to tackle drug resistant infections
  • 5.19. Takara Bio USA, Inc. and BioExcel Diagnostics Partner for Infectious Disease Panels
  • 5.20. Three companies join forces to tackle antimicrobial resistance (AMR)
  • 5.21. T2 Biosystems Exercises BARDA Option
  • 5.22. OpGen to Ramp up Use of Acuitas AMR Gene Panel
  • 5.23. BD Partners With Pfizer, Wellcome to Study AMR Dx
  • 5.24. Sepsis Test Developers Accelerate Plans
  • 5.25. OpGen Receives FDA Clearance for AMR Panel
  • 5.26. Visby Medical - Rapid Uptake of Handheld PCR Test for STIs
  • 5.27. MicroGenDx, OrthoKey Clinic and OrthoKey Surgery
  • 5.28. BioMerieux Receives CE Mark for Vitek Clinical Microbiology System
  • 5.29. Hologic to Acquire Mobidiag
  • 5.30. Campylobacter strains exchange genes
  • 5.31. Disinfection spreads antimicrobial resistance
  • 5.32. Molzym, Fraunhofer Developing Rapid Sepsis Dx
  • 5.33. Illumina, IDbyDNA Build NGS-Based Respiratory Panel
  • 5.34. Accelerate Diagnostics Expands AMR Testing
  • 5.35. Rapid diagnostics linked to optimal antibiotics
  • 5.36. Visby Medical Wins AMR Diagnostic Competition
  • 5.37. DNAe Technology SARS-CoV-2 Sequences
  • 5.38. Infections with foodborne bacteria becoming harder to treat
  • 5.39. Dust is sharing antibiotic resistance genes

6. Key AMR Diagnostics Companies

  • 6.1. 1928 Diagnostics
  • 6.2. Abbott Laboratories
  • 6.3. Accelerate Diagnostics
  • 6.4. ADT Biotech
  • 6.5. Beckman Coulter Diagnostics (Danaher)
  • 6.6. Becton, Dickinson and Company
  • 6.7. Binx Health
  • 6.8. bioMerieux Diagnostics
  • 6.9. Bio-Rad Laboratories, Inc.
  • 6.10. Cepheid (Danaher)
  • 6.11. Curetis (OpGen)
  • 6.12. Day Zero Diagnostics
  • 6.13. DeepUII Diagnostics
  • 6.14. DNAe
  • 6.15. Enzo Biochem
  • 6.16. Eurofins Scientific
  • 6.17. Fusion Genomics
  • 6.18. GeneFluidics
  • 6.19. Genetic Signatures
  • 6.20. Great Basin Scientific, Inc
  • 6.21. Hologic
  • 6.22. Hutman Diagnostics
  • 6.23. Inflammatix
  • 6.24. Linear Diagnostics
  • 6.25. Lumos Diagnostics
  • 6.26. MGI
  • 6.27. Millipore Sigma
  • 6.28. OpGen
  • 6.29. Pathogenomix
  • 6.30. Qiagen
  • 6.31. QuidelOrtho
  • 6.32. Revvity
  • 6.33. Roche Diagnostics
  • 6.34. Scope Fluidics
  • 6.35. SeLux Diagnostics
  • 6.36. Sherlock Biosciences
  • 6.37. Siemens Healthineers
  • 6.38. Sysmex
  • 6.39. Thermo Fisher Scientific
  • 6.40. Uniogen
  • 6.41. Vela Diagnostics
  • 6.42. Visby Medical

7. The Global Market for Antimicrobial Resistance Diagnostics

  • 7.1. Global Market Overview by Country
    • 7.1.1. Table - Global Market by Country
    • 7.1.2. Chart - Global Market by Country
  • 7.2. Global Market by Technology - Overview
    • 7.2.1. Table - Global Market by Pathogen
    • 7.2.2. Chart - Global Market by Pathogen - Base/End Year Comparison
    • 7.2.3. Chart - Global Market by Pathogen - Base Year
    • 7.2.4. Chart - Global Market by Pathogen - End Year
    • 7.2.5. Chart - Global Market by Pathogen - Share by Year
    • 7.2.6. Chart - Global Market by Pathogen - Segment Growth
  • 7.3. Global Market by Technology - Overview
    • 7.3.1. Table - Global Market by Technology
    • 7.3.2. Chart - Global Market by Technology - Base/End Year Comparison
    • 7.3.3. Chart - Global Market by Technology - Base Year
    • 7.3.4. Chart - Global Market by Technology - End Year
    • 7.3.5. Chart - Global Market by Technology - Share by Year
    • 7.3.6. Chart - Global Market by Technology - Segment Growth

8. Global Antibiotic Resistance Diagnostic Markets - By Pathogen

  • 8.1. Drug Resistant Streptococcus Pneumoniae - DRSP
    • 8.1.1. Table DRSP - by Country
    • 8.1.2. Chart - DRSP Growth
  • 8.2. Drug Resistant Campylobacter - DRC
    • 8.2.1. Table DRC - by Country
    • 8.2.2. Chart - DRC Growth
  • 8.3. Clostridium Difficile - CD
    • 8.3.1. Table CD - by Country
    • 8.3.2. Chart - CD Growth
  • 8.4. Methicillin Resistant Staphylococcus Aureus - MRSA
    • 8.4.1. Table MRSA - by Country
    • 8.4.2. Chart - MRSA Growth
  • 8.5. Drug Resistant Neisseria Gonorrhoeae - DRNG
    • 8.5.1. Table DRNG - by Country
    • 8.5.2. Chart - DRNG Growth
  • 8.6. Drug Resistant Salmonella - DRNTS
    • 8.6.1. Table DRNTS - by Country
    • 8.6.2. Chart - DRNTS Growth

9. Global Antibiotic Resistance Diagnostic Markets - by Technology

  • 9.1. Microbiology Culture
    • 9.1.1. Table Culture - by Country
    • 9.1.2. Chart - Culture Growth
  • 9.2. Immunoassay
    • 9.2.1. Table Immunoassay - by Country
    • 9.2.2. Chart - Immunoassay Growth
  • 9.3. PCR
    • 9.3.1. Table PCR - by Country
    • 9.3.2. Chart - PCR Growth
  • 9.4. NGS
    • 9.4.1. Table NGS - by Country
    • 9.4.2. Chart - NGS Growth
  • 9.5. Mass Spectrometry - MS
    • 9.5.1. Table MS - by Country
    • 9.5.2. Chart - MS Growth
  • 9.6. Rapid and Point of Care - Rapid/POC
    • 9.6.1. Table Rapid/POC - by Country
    • 9.6.2. Chart - Rapid/POC Growth

10. Vision of the Future of AMR Diagnostics

11. Appendices

  • 11.1. United States Medicare System: Clinical Laboratory Fees Schedule